In the traditional landscape of preclinical drug development, the journey of a tissue sample was linear and finite: a pathologist examined a slide, a report was filed, and the glass specimen was relegated to long-term storage—essentially a one-way street into obscurity. However, a seismic shift is underway in the field of digital pathology. Accelerated by the necessity of remote work during the pandemic, the transition from physical microscopy to high-resolution digital imaging has unlocked a treasure trove of biological data, promising to redefine the future of animal research and drug safety.
By applying sophisticated artificial intelligence (AI) and machine learning models to these digitized slides, researchers are now mining “old” tissue to answer “new” questions. This evolution not only maximizes the scientific utility of every sample but also aligns with a growing global mandate to reduce, refine, and replace animal testing (the 3Rs).
The Paradigm Shift: From Static Reports to Dynamic Data
For years, the "pathology endpoint" was synonymous with a static document. "Before, the pathology endpoint was just a report," explains Dr. Aleksandra Zuraw, a veterinary pathologist at Charles River Laboratories. "Now, you have the digitized slide, which is essentially pixels."
This shift to digital pixels has transformed archival tissue into a dynamic database. By pairing these high-resolution images with existing pathology reports and molecular measurements, researchers can train sophisticated computational models to recognize intricate patterns linked to molecular changes. A slide that was once used to determine basic toxicity can now be re-evaluated to understand drug-cell interactions at a molecular level, effectively turning an old experiment into a source of novel discovery.
Chronology: From Pandemic Necessity to Regulatory Mandate
The adoption of digital pathology has followed a distinct, rapid trajectory:
- 2020–2021 (The Catalyst): Global lockdowns necessitated a rapid transition to digital sign-outs as pathologists were physically barred from laboratories. This period forced the infrastructure for digital pathology to mature rapidly.
- 2022 (Legislative Milestone): The U.S. enacted the FDA Modernization Act 2.0, a landmark piece of legislation that officially authorized the use of non-animal methods to support human clinical trial applications, signaling a departure from the traditional requirement for animal data.
- 2024 (Strategic Integration): Charles River Laboratories launched its Alternative Methods Advancement Project, formalizing the institutional shift toward leveraging historical data and digital assets to minimize animal usage.
- 2025 (Guidance and Standardization): The OECD released critical guidance on sample collection for “omics” analysis, providing a framework for how preserved tissue can support complex molecular investigations.
- 2026 (The New Frontier): The FDA published an updated roadmap aimed at transitioning away from animal studies. By targeting monoclonal antibodies first, the agency set a three-to-five-year timeline for making New Approach Methodologies (NAMs) the standard in preclinical safety.
Supporting Data: Maximizing Utility in Toxicology
The primary challenge in preclinical toxicology is the sheer volume of animals required to establish robust control baselines. In a standard study, every treatment group must be paired with a "concurrent" control group—animals that are handled identically but receive no drug.
The Power of Virtual Control Groups
"Control animals represent a significant fraction of every study," Dr. Zuraw notes. By leveraging vast repositories of historical data, researchers are moving toward "virtual control groups." If a laboratory can demonstrate that its historical environmental and experimental conditions are consistent, it can replace a portion of the physical control animals with matched historical data. This simple arithmetic—reducing the number of animals required per study—is one of the most immediate and impactful ways to implement the 3Rs.
Unlocking FFPE Archives
Formalin-fixed, paraffin-embedded (FFPE) blocks remain the backbone of tissue archiving. While fresh-frozen tissue is ideal for molecular studies, it requires pre-planning that is not always possible when new questions arise mid-development. Today’s researchers are demonstrating that FFPE blocks, if stored properly, can still yield high-quality molecular information. By utilizing these existing blocks, scientists can perform gene expression or protein analyses that explain how a drug affected a specific organ system, often years after the original study concluded, without sacrificing a single additional animal.
Official Responses and Regulatory Outlook
The regulatory environment has shifted from cautious observation to active encouragement. The FDA’s recent initiatives, particularly the 2025–2026 roadmaps, reflect a clear administrative intent: animal testing should eventually be the exception, not the rule.
The FDA’s push toward NAMs is not merely an ethical stance; it is a recognition that digital and molecular models often provide higher-resolution data than traditional, subjective microscopic assessments. By standardizing the digital format, the FDA is essentially building a regulatory highway for AI-driven pathology to enter the approval process.
However, Dr. Zuraw emphasizes that institutional transition requires "early adopters." These laboratories are currently tasked with the "heavy lifting"—troubleshooting the integration of digital pathology into regulatory filings and providing the precedent that others will eventually follow. "You still need enough early adopters to generate precedent," she says. "They embrace the guidance, figure it out, and troubleshoot so others can build on their work without reinventing the wheel."
Implications: The Snowball Effect of Digital Innovation
The broader implications of this digital transition are profound. Beyond just saving animal lives, this approach promises to accelerate drug discovery timelines.
Virtual Staining and Beyond
Perhaps the most "cutting-edge" development is the rise of virtual staining. Currently, most digital pathology involves scanning a stained slide. However, researchers are now experimenting with capturing images of unstained tissue sections and using software to generate the appearance of a stain. This would, in theory, allow labs to skip the labor-intensive chemical staining process and the physical glass slide entirely.
While still in the developmental phase, the proliferation of virtual histology across diverse tissue types suggests that the industry is approaching a tipping point. As labs invest in the hardware and software required to digitize their archives, the cost-benefit analysis of digital pathology continues to favor the "all-digital" approach.
The "Snowball Effect"
Dr. Zuraw envisions a "snowball effect" where the availability of high-quality, digitized data creates a virtuous cycle. As the library of digitized tissues grows, the potential for AI models to discover novel, non-obvious patterns increases. This creates a data-rich environment where researchers can perform "experiments" on existing digital files—testing hypotheses, verifying safety, and exploring biological mechanisms without ever entering an animal facility.
Conclusion
The transformation of pathology from a subjective, physical science to a digital, data-driven discipline represents one of the most significant advancements in modern medicine. By treating archived tissue not as "dead data" but as a dynamic asset, the preclinical research community is finding a path that aligns commercial efficiency with ethical responsibility.
As the industry moves toward the FDA’s goal of making NAMs the default, the work being done today at institutions like Charles River—mining the past to secure the future—will serve as the foundation for a new era of drug discovery. The "next act" of digital pathology is not just about digitizing slides; it is about digitizing our understanding of biology itself, ensuring that every animal utilized in research contributes the maximum possible value to human health.
About the Author
